Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis

Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture

(2014) Johanna H.M. Driessen et al.   BONE

Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study

(2014) Willemijn L. Eppenga et al.   DIABETES CARE

Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA

(2014) D. Prieto-Alhambra et al.   OSTEOPOROSIS INTERNATIONAL

Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes

(2013) Ju-Young Kim et al.   LIFE SCIENCES

Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial

(2013) C. Klop et al.   OSTEOPOROSIS INTERNATIONAL

Risk of fracture in patients with Parkinson’s disease

(2013) S. Pouwels et al.   OSTEOPOROSIS INTERNATIONAL

Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)

(2013) Guillaume Mabilleau et al.   Journal of Diabetes

Potential Impact of Benzodiazepine Use on the Rate of Hip Fractures in Five Large European Countries and the United States

(2012) T. P. Khong et al.   CALCIFIED TISSUE INTERNATIONAL

Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

(2012) Marloes T. Bazelier et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials

(2011) M. Monami et al.   DIABETES CARE

Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes

(2011) Ann V. Schwartz   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states

(2011) Paola Moreno et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

(2010) M. C. Bunck et al.   DIABETES OBESITY & METABOLISM

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

(2010) D. J. Betteridge   DIABETIC MEDICINE

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

(2010) Bernardo Nuche-Berenguer et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Validation and validity of diagnoses in the General Practice Research Database: a systematic review

(2009) Emily Herrett et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States

(2009) Bernardo Nuche-Berenguer et al.   CALCIFIED TISSUE INTERNATIONAL

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states

(2009) Bernardo Nuche-Berenguer et al.   REGULATORY PEPTIDES

The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption

(2007) Chizumi Yamada et al.   ENDOCRINOLOGY